Rapid Treatment of HCV for People Who Inject Drugs to Increase Cure Rates
Premiere Date: Tuesday, December 21, 2021This activity offers CE credit for:
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, December 21, 2022
Note: Credit Is No Longer Available
 | Mark S. Gold, MD ASAM's Annual Lifetime Achievement John P. McGovern Award & Prize Winner Adjunct Professor of Psychiatry Washington University School of Medicine St. Louis, MO 17th University of Florida Distinguished Alumni Professor Gainesville, FL |
In this final installment of the Research You Can Use series, Dr. Gold will share the results and his insights on the findings from a poster presented at Infectious Disease Week (IDWeek 2021) and The Liver Meeting Digital Experience comparing Rapid Treatment and Usual Care in people who inject drugs with the goal of achieving sustained viral response (SVR12).
At the end of this CE activity, participants should be able to:
- Compare sustained hepatitis C viral response (SVR12) of rapid treatment with direct-acting antivirals (DAAs) compared to usual care to improve patient outcomes.
Supported by an educational grant from Gilead Sciences, Inc.
Primary care physicians, emergency medicine physicians, addiction specialists, harm reduction clinics, PAs, nurse practitioners, nurses, and pharmacists
ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gold has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Susan H. Yarbrough, CHCP (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
CN-046-122121-47
